Beiersdorf eyes U.S. opportunities
This article was originally published in The Rose Sheet
Executive Summary
Company it is interested in making acquisitions in the U.S. in order to strengthen its presence stateside, CEO Rolf Kunisch states during its annual meeting in Hamburg, Germany June 11. U.S. is firm's second largest market after Germany, with sales of more than $300 mil., exec reports. "Nevertheless, the U.S. is so big that increasing our sales even further would be helpful," he notes. Company expects consolidated 2003 sales to be up 7% at constant exchange rates, Kunisch projects...
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.